AI Assisted Medicine is fastest growing segment fueling the growth of Cancer Vaccines Market
Cancer vaccines help boost the body's natural defenses to recognize and fight cancer cells. They activate and aid the immune system to prevent or slow the growth of cancers like cervical cancer, prostate cancer etc. With the increasing prevalence of different types of cancers, cancer vaccines are gaining prominence as an effective preventive measure.
The global Cancer Vaccines Market is estimated to be
valued at US$ 1.9 Bn or billion in 2023 and is expected to exhibit a CAGR of
6.3% over the forecast period 2023 to 2030, as highlighted in a new report
published by Coherent Market Insights
Market key trends:
One of the major trends driving the growth
of the cancer vaccines market is the increasing focus on personalized cancer
vaccines. Conventional cancer vaccines are designed to target common mutations
found in many cancer patients. However, with advanced technologies like whole
genome sequencing, it has now become possible to design vaccines targeted
towards the specific mutations found in an individual patient's tumor. Such
personalized cancer vaccines have higher efficacy and are emerging as a
promising approach in cancer immunotherapy.
Segment Analysis
Content: The global cancer vaccines market
is segmented into preventive cancer vaccines and therapeutic cancer vaccines.
The preventive cancer vaccines segment currently dominates the market due to
increasing awareness about HPV vaccines to prevent cervical cancer. Preventive
HPV vaccines inhibit infection by HPV types 16 and 18 that are responsible for
70% of cervical cancer cases worldwide.
Key Takeaways
Market size: The global cancer vaccines
market is expected to witness high growth, exhibiting CAGR of 6.3% over the
forecast period, due to increasing awareness about cancer prevention through
vaccines and rising government initiatives for immunization programs.
Regional analysis: North America currently
dominates the cancer vaccines market due to high adoption of HPV vaccines in
the US and Canada. Asia Pacific is expected to be the fastest growing region
owing to growing healthcare expenditure and improving standard of living in
developing Asian countries.
Key players: Key players operating in the
cancer vaccines market are Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline
Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower
Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of
India Pvt. Ltd. GSK's bivalent HPV vaccine, Cervarix, leads the HPV vaccines
segment.
Comments
Post a Comment